Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Urogenital Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Sorafenib 12Radiosurgery 5Gemcitabine 5Capecitabine 5Bevacizumab 5Radiotherapy 4Fluorouracil 4Doxorubicin 4Sunitinib 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3seocalcitol 2regorafenib 2phosphomannopentaose sulfate 2atezolizumab 2Thiotepa 2Radiofrequency Ablation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Dexamethasone 2Cisplatin 2Chemoembolization, Therapeutic 2Carboplatin 2Busulfan 2Brachytherapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Liver Neoplasms × National Cancer Institute (U.S.) × Clear all
NCT03480152 2020-06-02

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 11 charts
DermatologicGastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡